Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Transcatheter Aortic Valve Replacement (TAVR)
Treatment for Non-rheumatic calcific aortic valve disease
Effectiveness
90%
Safety Score
45%
Clinical Trials
550
Participants
120K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate hemodynamic improvement, symptomatic relief within days to weeks
Treatment Duration
One-time procedure; valve durability 10-15+ years; initial procedure cost $30,000-$60,000.
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,500
Side Effect Mgmt:$1,000
Total Annual:$2,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
1.5
Comparison vs Surgical Aortic Valve Replacement (SAVR)
Cost Difference
+$5,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Transcatheter Aortic Valve Replacement (TAVR) Outcomes
for Non-rheumatic calcific aortic valve disease
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+98%
Common Side Effects
Vascular complications
+7%
Stroke
+3%
New pacemaker implantation
+15%
Paravalvular leak (moderate/severe)
+4%
Acute kidney injury
+8%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov